Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06312137
Title	A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme LLC
Indications	lung squamous cell carcinoma lung non-squamous non-small cell carcinoma
Therapies	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| GRC \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG